sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.
|
ketoconazole
|
budesonide
|
MECHANISM
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s0
|
DDI-DrugBank.d144.s0.p0
|
Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
|
Aminosalicylic acid
|
Lanoxin
|
MECHANISM
|
Aminosalicylic Acid_ddi.xml
|
DDI-DrugBank.d22.s0
|
DDI-DrugBank.d22.s0.p1
|
Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.
|
antacid
|
theophylline
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s32
|
DDI-DrugBank.d558.s32.p58
|
Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.
|
PAH
|
thiazolesulfone
|
EFFECT
|
Aminohippurate_ddi.xml
|
DDI-DrugBank.d416.s0
|
DDI-DrugBank.d416.s0.p2
|
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.
|
cholestyramine
|
cerivastatin sodium
|
MECHANISM
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s5
|
DDI-DrugBank.d141.s5.p0
|
When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.
|
Bezalip retard
|
Bezalip retard
|
NONE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s0
|
DDI-DrugBank.d291.s0.p5
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
cholestyramine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p8
|
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.
|
Ritonavir
|
Vardenafil
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s12
|
DDI-DrugBank.d198.s12.p0
|
Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.
|
Antihistamines
|
tranquilizers
|
EFFECT
|
Cyproheptadine_ddi.xml
|
DDI-DrugBank.d492.s1
|
DDI-DrugBank.d492.s1.p4
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
chlorpropamide
|
quinine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p483
|
Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.
|
anakinra
|
TNF-blocking agents
|
EFFECT
|
Adalimumab_ddi.xml
|
DDI-DrugBank.d493.s4
|
DDI-DrugBank.d493.s4.p0
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
Phenytoin
|
calcitriol
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s2
|
DDI-DrugBank.d98.s2.p4
|
Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
|
PRINIVIL
|
spironolactone
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s15
|
DDI-DrugBank.d334.s15.p1
|
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.
|
ritonavir
|
almotriptan
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s11
|
DDI-DrugBank.d299.s11.p11
|
There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.
|
hypoglycemic agents
|
diclofenac
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s11
|
DDI-DrugBank.d249.s11.p2
|
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.
|
neomycin
|
vitamin B-12
|
MECHANISM
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s2
|
DDI-DrugBank.d330.s2.p1
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
efavirenz
|
sulfamethoxazole
|
NONE
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p73
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
sedative-hypnotics
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p29
|
- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives
|
Lofexidine
|
barbiturates
|
EFFECT
|
Lofexidine_ddi.xml
|
DDI-DrugBank.d454.s0
|
DDI-DrugBank.d454.s0.p1
|
The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
phenothiazine derivatives
|
estrogens
|
NONE
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s2
|
DDI-DrugBank.d527.s2.p92
|
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
|
phenobarbital
|
phenobarbital
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s28
|
DDI-DrugBank.d434.s28.p14
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
cholestyramine
|
ferrous sulfate
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p19
|
H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.
|
L-histidine
|
H1 blockers
|
EFFECT
|
L-Histidine_ddi.xml
|
DDI-DrugBank.d365.s1
|
DDI-DrugBank.d365.s1.p7
|
Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.
|
probenecid
|
norfloxacin
|
MECHANISM
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s9
|
DDI-DrugBank.d217.s9.p2
|
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
|
EPA
|
aspirin
|
INT
|
Icosapent_ddi.xml
|
DDI-DrugBank.d35.s0
|
DDI-DrugBank.d35.s0.p0
|
Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.
|
Nicotinic Acid
|
Azole Antifungals
|
NONE
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s0
|
DDI-DrugBank.d141.s0.p13
|
The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
|
phenothiazines
|
dopamine antagonists
|
NONE
|
Gonadorelin_ddi.xml
|
DDI-DrugBank.d369.s3
|
DDI-DrugBank.d369.s3.p2
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
corticosteroids
|
diuretics
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p2
|
The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.
|
diuretic
|
PRINIVIL
|
EFFECT
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s1
|
DDI-DrugBank.d334.s1.p2
|
Consequently, the combination of methotrexate with acitretin is also contraindicated.
|
methotrexate
|
acitretin
|
ADVISE
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s9
|
DDI-DrugBank.d353.s9.p0
|
Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.
|
ketoconazole
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s8
|
DDI-DrugBank.d237.s8.p0
|
The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
|
CGS 21680
|
CPA
|
NONE
|
7746025.xml
|
DDI-MedLine.d51.s3
|
DDI-MedLine.d51.s3.p4
|
This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
|
thiosulfate
|
cisplatin
|
MECHANISM
|
4038510.xml
|
DDI-MedLine.d130.s8
|
DDI-MedLine.d130.s8.p0
|
The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.
|
zopiclone
|
ROMAZICON
|
EFFECT
|
Flumazenil_ddi.xml
|
DDI-DrugBank.d234.s6
|
DDI-DrugBank.d234.s6.p0
|
Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.
|
tacrolimus
|
bosentan
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s15
|
DDI-DrugBank.d289.s15.p0
|
Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.
|
Levo-Dromoran
|
hypnotics
|
EFFECT
|
Levorphanol_ddi.xml
|
DDI-DrugBank.d257.s0
|
DDI-DrugBank.d257.s0.p3
|
Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.
|
levothyroxine sodium
|
cholestyramine
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s2
|
DDI-DrugBank.d411.s2.p8
|
Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.
|
VIOXX
|
lithium
|
ADVISE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s18
|
DDI-DrugBank.d210.s18.p0
|
Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.
|
isoniazid
|
valproate
|
ADVISE
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s14
|
DDI-DrugBank.d187.s14.p3
|
Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).
|
Antibiotics
|
sulfamethoxazole
|
NONE
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s11
|
DDI-DrugBank.d367.s11.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
bacitracin
|
clindamycin
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p52
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
heparin
|
thiazide diuretics
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p424
|
Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.
|
atenolol
|
warfarin
|
NONE
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s1
|
DDI-DrugBank.d533.s1.p11
|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
antihistamines
|
levodopa
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p72
|
Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.
|
phenobarbital
|
flecainide
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s13
|
DDI-DrugBank.d87.s13.p4
|
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;
|
amitriptyline
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s41
|
DDI-DrugBank.d485.s41.p7
|
Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
|
diltiazem
|
sirolimus
|
MECHANISM
|
11180036.xml
|
DDI-MedLine.d86.s0
|
DDI-MedLine.d86.s0.p0
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
fluoxetine
|
5-HT1 agonists
|
EFFECT
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p14
|
OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine.
|
hydrocortisone
|
d-amphetamine
|
NONE
|
11271411.xml
|
DDI-MedLine.d38.s3
|
DDI-MedLine.d38.s3.p0
|
Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.
|
thiazide diuretics
|
allopurinol
|
NONE
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s12
|
DDI-DrugBank.d413.s12.p5
|
Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol (felbamate) plasma concentrations.
|
Felbatol
|
felbamate
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s32
|
DDI-DrugBank.d434.s32.p14
|
In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.
|
iloprost
|
captopril
|
NONE
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s0
|
DDI-DrugBank.d549.s0.p2
|
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
|
acetaminophen
|
theophylline
|
EFFECT
|
11206047.xml
|
DDI-MedLine.d111.s14
|
DDI-MedLine.d111.s14.p0
|
Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.
|
corticosteroids
|
amphotericin B
|
ADVISE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s1
|
DDI-DrugBank.d314.s1.p3
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
bromocriptine
|
calcium
|
NONE
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p46
|
Coadministration of valdecoxib and Ortho-Novum 1/35 increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.
|
valdecoxib
|
Ortho-Novum
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s44
|
DDI-DrugBank.d328.s44.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
trimethoprim
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p12
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
midazolam
|
tramadol
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p858
|
A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.
|
Vardenafil
|
ketoconazole
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s8
|
DDI-DrugBank.d198.s8.p0
|
CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
|
eszopiclone
|
ethanol
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s0
|
DDI-DrugBank.d216.s0.p4
|
Amphetamines may enhance the effects of tricyclic antidepressants.
|
Amphetamines
|
tricyclic antidepressants
|
EFFECT
|
Benzphetamine_ddi.xml
|
DDI-DrugBank.d477.s3
|
DDI-DrugBank.d477.s3.p0
|
Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
|
acitretin
|
tetracyclines
|
EFFECT
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s11
|
DDI-DrugBank.d353.s11.p2
|
Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.
|
MAOIs
|
clidinium
|
EFFECT
|
Clidinium_ddi.xml
|
DDI-DrugBank.d322.s0
|
DDI-DrugBank.d322.s0.p5
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
benzocaine
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p5
|
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.
|
risperidone
|
levodopa
|
EFFECT
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s2
|
DDI-DrugBank.d47.s2.p13
|
Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.
|
ethanol
|
tiagabine
|
ADVISE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s23
|
DDI-DrugBank.d277.s23.p1
|
Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
|
felodipine
|
phenytoin
|
MECHANISM
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s14
|
DDI-DrugBank.d316.s14.p6
|
Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
|
nelfinavir
|
ritonavir
|
NONE
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s32
|
DDI-DrugBank.d485.s32.p12
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
chlordiazepoxide
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p14
|
Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
|
ciprofloxacin
|
sulfonylurea
|
EFFECT
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s3
|
DDI-DrugBank.d123.s3.p3
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
fluoxetine
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p9
|
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
|
benzodiazepines
|
barbiturates
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s3
|
DDI-DrugBank.d335.s3.p0
|
Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
|
verapamil
|
bombesin
|
EFFECT
|
11125235.xml
|
DDI-MedLine.d133.s0
|
DDI-MedLine.d133.s0.p0
|
Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects
|
Accutane
|
vitamin A
|
NONE
|
Isotretinoin_ddi.xml
|
DDI-DrugBank.d163.s0
|
DDI-DrugBank.d163.s0.p6
|
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
|
hypnotics
|
insulin
|
NONE
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s12
|
DDI-DrugBank.d507.s12.p28
|
Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.
|
spironolactone
|
amiloride
|
NONE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s4
|
DDI-DrugBank.d561.s4.p4
|
There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.
|
theophylline
|
theophylline
|
NONE
|
Nalidixic Acid_ddi.xml
|
DDI-DrugBank.d427.s1
|
DDI-DrugBank.d427.s1.p1
|
Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.
|
Itraconazole
|
midazolam
|
MECHANISM
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s11
|
DDI-DrugBank.d165.s11.p0
|
Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor.
|
reverse transcriptase inhibitors
|
protease inhibitor
|
NONE
|
11148572.xml
|
DDI-MedLine.d115.s5
|
DDI-MedLine.d115.s5.p2
|
Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;
|
Aprepitant
|
ethinyl estradiol
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s19
|
DDI-DrugBank.d382.s19.p7
|
INDOCIN can reduce the antihypertensive effects of captopril and losartan.
|
INDOCIN
|
captopril
|
EFFECT
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s35
|
DDI-DrugBank.d82.s35.p0
|
This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).
|
aspirin
|
nonsteroidal anti-inflammatory drugs
|
NONE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s5
|
DDI-DrugBank.d529.s5.p0
|
Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).
|
dextromethorphan
|
MAOIs
|
EFFECT
|
Guaifenesin_ddi.xml
|
DDI-DrugBank.d398.s1
|
DDI-DrugBank.d398.s1.p1
|
Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.
|
diflunisal
|
methotrexate
|
ADVISE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s16
|
DDI-DrugBank.d132.s16.p2
|
Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.
|
Auranofin
|
Myochrysine
|
ADVISE
|
Auranofin_ddi.xml
|
DDI-DrugBank.d374.s0
|
DDI-DrugBank.d374.s0.p2
|
The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
|
ENABLEX
|
itraconazole
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s0
|
DDI-DrugBank.d459.s0.p1
|
When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.
|
ketoconazole
|
coumarin
|
EFFECT
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s19
|
DDI-DrugBank.d458.s19.p2
|
Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.
|
phenobarbital
|
fenoprofen
|
MECHANISM
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s3
|
DDI-DrugBank.d154.s3.p0
|
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
|
FACTIVE
|
calcium carbonate
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s1
|
DDI-DrugBank.d347.s1.p0
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
zinc
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p41
|
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.
|
Furosemide
|
ethacrynic acid
|
ADVISE
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s2
|
DDI-DrugBank.d231.s2.p0
|
Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.
|
diuretics
|
fosinopril sodium
|
EFFECT
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s0
|
DDI-DrugBank.d176.s0.p2
|
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
|
PROLEUKIN
|
cis-platinum
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s5
|
DDI-DrugBank.d114.s5.p2
|
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
|
cysteine
|
NaFlu
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s10
|
DDI-MedLine.d76.s10.p4
|
To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.
|
delavirdine
|
indinavir
|
NONE
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s15
|
DDI-DrugBank.d43.s15.p0
|
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.
|
zalcitabine
|
antacids
|
ADVISE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s23
|
DDI-DrugBank.d263.s23.p2
|
Cytadren accelerates the metabolism of dexamethasone;
|
Cytadren
|
dexamethasone
|
MECHANISM
|
Aminoglutethimide_ddi.xml
|
DDI-DrugBank.d372.s0
|
DDI-DrugBank.d372.s0.p0
|
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
|
tetracyclines
|
calcium
|
MECHANISM
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s2
|
DDI-DrugBank.d500.s2.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Sporanox
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p15
|
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.
|
bepridil hydrochloride
|
quinidine
|
NONE
|
Bepridil_ddi.xml
|
DDI-DrugBank.d137.s9
|
DDI-DrugBank.d137.s9.p1
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.